IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

This trial is testing a new type of immune cell therapy called IX001 TCR-T — immune cells engineered to recognize and attack cancer cells with specific KRAS mutations — in adults with advanced pancreatic cancer or colorectal cancer whose tumors carry one of these specific genetic changes. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced pancreatic cancer or colorectal cancer confirmed by tissue testing - Your cancer has failed at least two standard treatment regimens - Your tumor or blood tests show a KRAS-G12V or G12D mutation and you carry specific immune system markers (HLA subtypes) - You have at least one measurable tumor and adequate organ function - You have a good performance status (ECOG 0-2) and a life expectancy of at least 3 months **You may NOT be eligible if...** - Your tumor does not have the required KRAS mutation or HLA markers - Your cancer has not failed two prior treatment regimens - You have severe organ dysfunction or very low blood counts - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.